More than 32m Americans already use cannabis. As the business becomes more normalised, it is sure to attract new customers. “It’s not often that you see an industry and you know the inevitability of it,” says Brendan Kennedy of Privateer Holdings, a private-equity firm that specialises in cannabis.

“I think people will derive more benefit if they can speak more openly with providers about whether they are using cannabis and why,” says Walsh. Walsh is a lead investigator on a clinical trial of cannabis that is being funded by a medical cannabis producer called Tilray.

Clearly good beauty runs in the family, as all of the treatments (as well as the in-room amenities) come from Marley Natural, a hemp-seed-oil-based apothecary line started up in partnership with the Marley family that features botanicals and essential oils native to Jamaica. A portion of the proceeds from the range also goes toward Rise Up, a nonprofit that supports Jamaican culture and sustainability, among other community-oriented initiatives.

Brendan Kennedy, the cofounder of Privateer Holdings, which owns various marijuana companies like Marley Natural and Canadian pharmaceutical-grade cannabis producer Tilray, explains how Tilray is already exporting marijuana to countries like Croatia and Australia for use in clinical trials.

Brendan Kennedy, CEO of Privateer Holdings, a Seattle-based private-equity firm that has several cannabis companies, said he sees opportunities for Canadian firms to license their brand to local American producers. He added that Tilray, a Nanaimo, B.C.-based medical grower owned by Privateer, will continue to pursue export and partnership opportunities in Australia and European countries, where medical marijuana is closer to becoming legalized nationally.